US 11,873,512 B2
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
Dario Campana, Singapore (SG); and Yu-Hsiang Chang, Kaohsiung (TW)
Assigned to St. Jude Children's Research Hospital, Inc., Memphis, TN (US); and National University of Singapore, Singapore (SG)
Filed by St. Jude Children's Research Hospital, Inc., Memphis, TN (US); and National University of Singapore, Singapore (SG)
Filed on Oct. 9, 2020, as Appl. No. 17/067,016.
Application 17/067,016 is a continuation of application No. 15/857,315, filed on Dec. 28, 2017, granted, now 10,836,999.
Application 15/857,315 is a continuation of application No. 15/337,854, filed on Oct. 28, 2016, granted, now 10,538,739, issued on Jan. 21, 2020.
Application 15/337,854 is a continuation of application No. 14/764,070, granted, now 9,511,092, issued on Dec. 6, 2016, previously published as PCT/US2014/013292, filed on Jan. 28, 2014.
Claims priority of provisional application 61/757,481, filed on Jan. 28, 2013.
Prior Publication US 2021/0115404 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 38/00 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 35/17 (2015.01); C12N 5/00 (2006.01)
CPC C12N 5/0646 (2013.01) [A61K 35/17 (2013.01); A61K 38/00 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/7056 (2013.01); C12N 5/0087 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01); C12N 2510/00 (2013.01)] 19 Claims
 
1. A method of producing a population of natural killer (NK) cells for use in treating cancer, said method comprising:
obtaining a peripheral blood sample comprising a mixed population of mononuclear cells comprising NK cells and T cells,
culturing said mixed population of mononuclear cells under culture conditions resulting in the enhanced expansion of NK cells, and
introducing into the NK cells a nucleic acid encoding a chimeric receptor, the chimeric receptor comprising:
i) an extracellular receptor domain, wherein said extracellular receptor domain comprises a fragment of NKG2D that binds one or more of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6, and
ii) a CD3 zeta cytoplasmic domain.